Mounjaro (tirzepatide) is a once-weekly injectable medication developed by Eli Lilly, featuring dual action on GIP and GLP-1 receptors. It is FDA-approved for type 2 diabetes management and has been investigated under the designation Zepbound for additional metabolic indications. The 5 mg concentration is a documented step-up dose from the initial 2.5 mg titration phase, studied for its role in glycemic regulation and incretin-mediated appetite modulation.
✔ Key Research Insights
- ✔ Studied for its role in HbA1c reduction in type 2 diabetes research subjects across clinical trials
- ✔ Investigated for its influence on body weight parameters, with significant reductions documented in clinical literature
- ✔ Examined for its pharmacological convenience as a once-weekly administration format supporting protocol adherence
- ✔ Researched for its dual incretin mechanism, including effects on insulin secretion, glucagon suppression, and appetite-related signalling pathways
📦 Product Specifications
- Manufacturer: Eli Lilly
- Molecule: Tirzepatide
- Mechanism: Dual GIP and GLP-1 receptor agonist
- Concentration: 5 mg
- Form: 5 mg vial / 4 vial in Box /
- Administration: Once-weekly subcutaneous injection
- Clinical reference: Dosage considerations may vary. Consulting a qualified healthcare professional is recommended.
⚙ How It Works
Tirzepatide acts simultaneously on glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In research subjects, this dual receptor engagement has been documented to enhance glucose-dependent insulin release, suppress glucagon secretion, and modulate appetite signalling through central and peripheral pathways. Clinical literature supports its role in improving glycemic parameters and influencing body weight outcomes in populations with type 2 diabetes and related metabolic conditions.
⭐ Product Overview
- Developed by Eli Lilly, a globally recognized pharmaceutical manufacturer
- Features a novel dual incretin mechanism distinguishing it from single-receptor GLP-1 agonists
- FDA-approved compound with documented clinical trial data across glycemic and metabolic endpoints
- Once-weekly pre-filled injectable pen format supporting consistent administration
- Investigated across multiple indications under both the Mounjaro and Zepbound designations
📌 Clinical Administration Notes
- Titration from 2.5 mg is the documented initiation protocol, designed to support gastrointestinal tolerability
- Small, frequent meals and avoidance of high-fat or high-spice foods are commonly referenced in tolerability guidance
- Adequate hydration is advised, particularly during the early phases of administration
Mounjaro 5 mg / 4 vial in Box / Tirzepatide Thailand
✅ Step-by-Step: How to Use Mounjaro
Start with the Right Dose
- Initial dose: 2.5 mg once weekly for the first 4 weeks
- Increase to: 5 mg after 4 weeks
- Optional escalation: Gradually increase every 4 weeks
Pick Your Injection Day
- Choose one fixed day per week (e.g., every Monday)
- You can change your injection day if there are at least 72 hours (3 days) between doses
Storage & Prep
- Store unopened pens in the fridge (2–8°C)
- Can be kept at room temp (<30°C) for up to 21 days
- Do not freeze, shake, or expose to sunlight
Injection Technique
- Clean the injection site: abdomen, thigh, or upper arm
- Rotate sites weekly to avoid irritation
- Use the prefilled auto-injector pen (no need to see the needle)
- Press firmly and hold for 10 seconds until you hear a click and see the indicator
Missed Dose?
- If it’s within 4 days (96 hours) of the scheduled time: inject it immediately
- If it’s after 4 days: skip and wait for the next scheduled dose
- Never take two doses within 72 hours
Mounjaro’s active ingredient, tirzepatide, is a synthetic peptide that activates two hormone receptors simultaneously:
GIP (Glucose-dependent Insulinotropic Polypeptide)
- Stimulates insulin release after meals
- Improves the body’s response to insulin
- Reduces fat storage by improving lipid metabolism
- Enhances the effectiveness of GLP-1
GLP-1 (Glucagon-like Peptide-1)
- Suppresses appetite via brain signaling (hypothalamus)
- Slows gastric emptying → keeps you full longer
- Reduces glucagon (a hormone that raises blood sugar)
- Promotes weight loss and lowers blood sugar
🧪 In Summary:
Mounjaro mimics natural gut hormones but in a much stronger and longer-acting form, resetting the metabolic system, curbing hunger, improving insulin use, and accelerating fat loss. It's not just treating symptoms—it’s retraining your metabolism.
